Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients With Recurrent Glioblastoma in Spain
Value in Health - United Kingdom
doi 10.1016/j.jval.2014.08.2298
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2014
Authors
Publisher
Elsevier BV